-+ 0.00%
-+ 0.00%
-+ 0.00%

HSBC Downgrades Biogen to Reduce, Lowers Price Target to $143

Benzinga·12/10/2025 11:59:06
Listen to the news
HSBC analyst Rajesh Kumar downgrades Biogen (NASDAQ:BIIB) from Hold to Reduce and lowers the price target from $144 to $143.